Compare OPAL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | GANX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 74.6M |
| IPO Year | 2021 | 2021 |
| Metric | OPAL | GANX |
|---|---|---|
| Price | $2.23 | $1.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.72 | ★ $7.50 |
| AVG Volume (30 Days) | 307.2K | ★ 796.8K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | $55,180.00 |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $1.41 |
| 52 Week High | $2.87 | $4.34 |
| Indicator | OPAL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 47.23 |
| Support Level | $2.01 | $1.66 |
| Resistance Level | $2.35 | $2.15 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 43.44 | 50.00 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.